Bybee D E, Wiesen M, Aronin N, Krieger D T, Frohman L A, Kopin I J
J Clin Endocrinol Metab. 1982 Mar;54(3):648-50. doi: 10.1210/jcem-54-3-648.
A plasma catecholamine-lowering effect of bromocriptine has previously been reported in normals, but not in patients with PRL- or GH-secreting pituitary tumors, and has been used as evidence to support the concept of disordered central nervous system dopaminergic tone in patients with such tumors and as a test to distinguish them from normals. In the present study of 16 normal subjects (9 women and 7 men), we found no significant change in plasma norepinephrine or epinephrine after bromocriptine. Similarly, no change occurred in plasma catecholamines in 8 patients with PRL-secreting tumors or 6 patients with ACTH hypersecretion. Our data, therefore, do not provide confirmatory evidence for an effect of bromocriptine on plasma catecholamines in normal subjects and do not support the proposed use of bromocriptine as a test for defective central dopaminergic regulation.
先前有报道称，溴隐亭对正常人有降低血浆儿茶酚胺的作用，但对分泌催乳素或生长激素的垂体瘤患者则无此作用，该作用已被用作证据支持此类肿瘤患者中枢神经系统多巴胺能张力紊乱的概念，并作为将他们与正常人区分开来的一项检测。在本项针对16名正常受试者（9名女性和7名男性）的研究中，我们发现给予溴隐亭后，血浆去甲肾上腺素或肾上腺素无显著变化。同样，8例分泌催乳素肿瘤患者和6例促肾上腺皮质激素分泌过多患者的血浆儿茶酚胺也未发生变化。因此，我们的数据并未证实溴隐亭对正常受试者血浆儿茶酚胺有影响，也不支持将溴隐亭用作检测中枢多巴胺能调节缺陷的方法。
